Chemomab Therapeutics reports publication on its CCL24 target, SSc

Chemomab Therapeutics announced the publication of a new study that further confirms the key role of its novel soluble protein target CCL24 in systemic sclerosis, SSc. The study, “Serum CCL24 as a Biomarker of Fibrotic and Vascular Disease Severity in Systemic Sclerosis,” was published in the current edition of the journal Arthritis Care and Research. “This important new longitudinal study in a large cohort of patients with SSc further confirms the extensive body of preclinical evidence we have generated showing that CCL24 is a key driver of the skin, lung and vascular complications in this terrible condition that lacks disease-modifying therapies,” said Adi Mor, PhD, a co-author of the publication and co-founder, CEO and CSO of Chemomab. “These results also reinforce our belief, based on multiple preclinical and patient sample studies, that our novel CCL24-neutralizing antibody CM-101 has substantial potential as a treatment for SSc. Our SSc program is Phase 2-ready with an open US IND, with possible initiation of patient enrollment after the topline readout from our Phase 2 trial in primary sclerosing cholangitis that is expected in the next few months.”